7775 — Daiken Medical Co Income Statement
0.000.00%
Last trade - 00:00
- ¥16bn
- ¥16bn
- ¥9bn
- 100
- 56
- 82
- 96
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 8,407 | 8,523 | 7,862 | 8,540 | 9,137 |
Cost of Revenue | |||||
Gross Profit | 3,938 | 3,734 | 3,359 | 3,684 | 3,530 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7,249 | 7,348 | 6,953 | 7,391 | 8,111 |
Operating Profit | 1,157 | 1,175 | 909 | 1,150 | 1,026 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,154 | 1,191 | 945 | 1,151 | 1,025 |
Provision for Income Taxes | |||||
Net Income After Taxes | 852 | 860 | 675 | 831 | 712 |
Net Income Before Extraordinary Items | |||||
Net Income | 852 | 860 | 675 | 831 | 712 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 852 | 860 | 675 | 831 | 712 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 31.4 | 30.4 | 23.8 | 29 | 25.5 |
Dividends per Share |